Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China National Pharmaceutical Foreign Trade To Build Investment Platform For Pharmaceutical Industry

This article was originally published in PharmAsia News

Executive Summary

China National Pharmaceutical Foreign Trade Corporation, the wholly owned subsidiary of China National Pharmaceutical Group, has mapped out its medium- and long-term strategy that seeks strategic partnerships to establish an investment platform for the pharmaceutical industry. This will dovetail with the parent group's aim of consolidation and globalization of its pharmaceutical trade, technology and business. The trade corporation has collaborated with Otsuka Group, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, AstraZeneca and Kanebo and set up more than 10 joint ventures such as China Otsuka, Xian-Janssen, Shanghai Squibb, Suzhou Capsugel and Sino-Swed Pharmaceutical. It reported revenue of RMB 2 billion last year, with import and export amounting to RMB $300 million. (Click here for more - Chinese Language)

You may also be interested in...

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

Pfizer Confirms EU Pegfilgrastim Launch Plans

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts